
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio is poised for success as their pipeline, including lead candidate PBFT02, targets critical underlying pathologies in neurodegenerative diseases. While their focus on one-time gene therapies is a promising approach, the regulatory hurdles for these types of treatments should not be overlooked, as evidenced by Eli Lilly's recent program discontinuation due to lack of compelling efficacy. Despite this, Passage Bio's strong financial position with $302.7 million in cash and investments as of September 30, 2021, provides the necessary resources to potentially overcome any regulatory challenges.
Bears say
Passage Bio is a clinical-stage genetic medicines company with a single reportable segment focused on developing and advancing genetic medicines targeting neurodegenerative diseases. While the company has a robust pipeline and strong biomarker data, their limited resources and the challenges faced by all gene therapy programs make their planned registrational study for their lead program, PBFT02, nearly impossible. In addition, their focus on a disease with no treatment options may not be enough to convince the FDA to provide a flexible regulatory pathway.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares